Yuko Kaneyasu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yuko Kaneyasu has a total of 84 co-authors. Here are the top co-authors by number of shared publications:
- Masahiro Kenjo
Hiroshima University Hospital, Hiroshima, Japan
8 shared publications T Okawa
8 shared publicationsK Karasawa
7 shared publicationsT. Kimura
7 shared publicationsY. Murakami
7 shared publicationsY. Nagata
7 shared publications
Latest Publications
- 1 October 2013
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 87 (2) , S290-S291
Twenty Year Treatment Results of Radiation Therapy for T1N0M0 Esophageal Cancer
- 1 October 2013
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 87 (2) , S290-S291
Twenty Year Treatment Results of Radiation Therapy for T1N0M0 Esophageal Cancer
- 1 October 2013
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 87 (2) , S639
The Mechanism of a Novel Radioprotector, 8-Quinolinol Derivative KH-3
- 1 October 2013
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 87 (2) , S639
The Mechanism of a Novel Radioprotector, 8-Quinolinol Derivative KH-3
- Open Access
- 8 June 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 139
Distribution patterns of metastatic pelvic lymph nodes assessed by CT/MRI in patients with uterine cervical cancer
To investigate the three-dimensional (3D) distribution patterns of clinically metastatic (positive) lymph nodes on pretreatment computed tomography (CT)/magnetic resonance imaging (MRI) images of patients with locally advanced cervical cancer.
- 8 June 2013
- Published by Springer Nature in Radiation Oncology
- Vol. 8 (1) , 139
Open AccessDistribution patterns of metastatic pelvic lymph nodes assessed by CT/MRI in patients with uterine cervical cancer
To investigate the three-dimensional (3D) distribution patterns of clinically metastatic (positive) lymph nodes on pretreatment computed tomography (CT)/magnetic resonance imaging (MRI) images of patients with locally advanced cervical cancer.
- 12 July 2011
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 17 (3) , 263-271
Long-term outcomes of intraluminal brachytherapy in combination with external beam radiotherapy for superficial esophageal cancer
The aim of this study was to assess the long-term outcomes of combining high-dose-rate intraluminal brachytherapy (IBT) with external beam radiotherapy (EBRT) for superficial esophageal cancer (SEC). From 1992 to 2002, 87 patients with T1N0M0 thoracic esophageal cancer received IBT in combination with EBRT. Of these, 44 had mucosal cancer and 43 had submucosal cancer. For patients with tumor invasion within the lamina propria mucosa, IBT alone was performed (n = 27). IBT boost following EBRT was performed for patients with tumor invasion in the muscularis mucosa or deeper (n = 60). No patient received chemotherapy. The median follow-up time was 94 months. For mucosal cancer, the 5-year locoregional control (LRC), cause-specific survival (CSS) and overall survival (OS) rates were 75, 97 and 84%, respectively, and 49, 55 and 31%, respectively, for submucosal cancer. Tumor depth was a significant factor associated with LRC (p = 0.02), CSS (p < 0.001) and OS (p < 0.001) by univariate analysis. Multivariate analysis revealed that tumor depth was the only significant predictor for OS (p = 0.003). Late toxicities of grade 3 or higher in esophagus, pneumonitis, pleural effusion and pericardial effusion were observed in 5, 0, 0 and 1 patients, respectively. Grade ≥3 events of cardiac ischemia and heart failure after radiotherapy were observed in 9 patients, and history of heart disease before radiotherapy was the only significant factor (p = 0.002). There was a clear difference in outcomes of IBT combined with EBRT between mucosal and submucosal esophageal cancers. More intensive treatment should be considered for submucosal cancer.
- 12 July 2011
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 17 (3) , 263-271
Long-term outcomes of intraluminal brachytherapy in combination with external beam radiotherapy for superficial esophageal cancer
The aim of this study was to assess the long-term outcomes of combining high-dose-rate intraluminal brachytherapy (IBT) with external beam radiotherapy (EBRT) for superficial esophageal cancer (SEC). From 1992 to 2002, 87 patients with T1N0M0 thoracic esophageal cancer received IBT in combination with EBRT. Of these, 44 had mucosal cancer and 43 had submucosal cancer. For patients with tumor invasion within the lamina propria mucosa, IBT alone was performed (n = 27). IBT boost following EBRT was performed for patients with tumor invasion in the muscularis mucosa or deeper (n = 60). No patient received chemotherapy. The median follow-up time was 94 months. For mucosal cancer, the 5-year locoregional control (LRC), cause-specific survival (CSS) and overall survival (OS) rates were 75, 97 and 84%, respectively, and 49, 55 and 31%, respectively, for submucosal cancer. Tumor depth was a significant factor associated with LRC (p = 0.02), CSS (p < 0.001) and OS (p < 0.001) by univariate analysis. Multivariate analysis revealed that tumor depth was the only significant predictor for OS (p = 0.003). Late toxicities of grade 3 or higher in esophagus, pneumonitis, pleural effusion and pericardial effusion were observed in 5, 0, 0 and 1 patients, respectively. Grade ≥3 events of cardiac ischemia and heart failure after radiotherapy were observed in 9 patients, and history of heart disease before radiotherapy was the only significant factor (p = 0.002). There was a clear difference in outcomes of IBT combined with EBRT between mucosal and submucosal esophageal cancers. More intensive treatment should be considered for submucosal cancer.
- 1 February 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (4_suppl) , 89
Outcomes of chemoradiotherapy with a high irradiation dose using a 3D radiation treatment planning system for esophageal cancer.
89 Background: The standard irradiation dose of chemoradiotherapy (CRT) for esophageal cancer is 50.4 Gy, however, the trials in which this standard dose was originated were based on 2D radiation treatment planning. In this study we assessed the survival and toxicities of CRT with a dose of 60-66 Gy using a 3D radiation treatment planning system (3DRTPS) for esophageal cancer. Methods: One hundred and two eligible patients with esophageal cancer treated by definitive CRT between 2000 and 2006 were assessed. Median age was 67 years old. There were stage I in 22 patients, stage II-III (without T4) in 27 and T4/M1Lymph legions in 53. There were 100 patients with squamous cell carcinoma histology and 2 with small cell carcinoma. Main tumor sites were cervical/upper/middle/lower thoracic in 15/19/43/25 patients. Treatment planning of irradiation was performed using a CT based 3DRTPS. Total irradiation dose of our protocol was 60-66 Gy. Accomplishment rate of planned irradiation was 93%. All patients received chemotherapy concurrently with radiotherapy. Fluorouracil based chemotherapy was performed in 96 patients (94%). Results: The data was updated in August 2010. The median follow-up was 67 months. Cause-specific survival rates at 5 years for stage I, II-III (without T4) and T4/M1lymph were 100%, 49% and 17%, respectively and overall survival rates were 66%, 35% and 13%, respectively. Complete response (CR) rates were 100%, 79% and 35%, respectively and failure rates of CR cases were 5%, 43% and 42%, respectively. Late adverse effects (≥ grade 3) were observed in 11 patients (10%); pneumonitis in 4 (4%), pleural effusion in 4 (4%) and pericardial effusion in 5 (5%). Treatment related deaths were observed in 2 cases (pneumonitis developed during treatment in 1 and debility due to treatment in 1). Conclusions: Toxicities of CRT with a high irradiation dose using 3DRTPS for esophageal cancer were acceptable and survival was promising. Dose intensification study of 50.4 Gy versus ≥ 60 Gy in CRT using a 3D-conformal radiation therapy technique for esophageal cancer should be considered. No significant financial relationships to disclose.
- 1 February 2011
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (4_suppl) , 89
Outcomes of chemoradiotherapy with a high irradiation dose using a 3D radiation treatment planning system for esophageal cancer.
89 Background: The standard irradiation dose of chemoradiotherapy (CRT) for esophageal cancer is 50.4 Gy, however, the trials in which this standard dose was originated were based on 2D radiation treatment planning. In this study we assessed the survival and toxicities of CRT with a dose of 60-66 Gy using a 3D radiation treatment planning system (3DRTPS) for esophageal cancer. Methods: One hundred and two eligible patients with esophageal cancer treated by definitive CRT between 2000 and 2006 were assessed. Median age was 67 years old. There were stage I in 22 patients, stage II-III (without T4) in 27 and T4/M1Lymph legions in 53. There were 100 patients with squamous cell carcinoma histology and 2 with small cell carcinoma. Main tumor sites were cervical/upper/middle/lower thoracic in 15/19/43/25 patients. Treatment planning of irradiation was performed using a CT based 3DRTPS. Total irradiation dose of our protocol was 60-66 Gy. Accomplishment rate of planned irradiation was 93%. All patients received chemotherapy concurrently with radiotherapy. Fluorouracil based chemotherapy was performed in 96 patients (94%). Results: The data was updated in August 2010. The median follow-up was 67 months. Cause-specific survival rates at 5 years for stage I, II-III (without T4) and T4/M1lymph were 100%, 49% and 17%, respectively and overall survival rates were 66%, 35% and 13%, respectively. Complete response (CR) rates were 100%, 79% and 35%, respectively and failure rates of CR cases were 5%, 43% and 42%, respectively. Late adverse effects (≥ grade 3) were observed in 11 patients (10%); pneumonitis in 4 (4%), pleural effusion in 4 (4%) and pericardial effusion in 5 (5%). Treatment related deaths were observed in 2 cases (pneumonitis developed during treatment in 1 and debility due to treatment in 1). Conclusions: Toxicities of CRT with a high irradiation dose using 3DRTPS for esophageal cancer were acceptable and survival was promising. Dose intensification study of 50.4 Gy versus ≥ 60 Gy in CRT using a 3D-conformal radiation therapy technique for esophageal cancer should be considered. No significant financial relationships to disclose.
- 1 November 2010
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 78 (3) , S169
Sequential Chemoradiotherapy with 24 Gy of Cranial Irradiation for Intracranial Germinoma diagnosed with MRI
- 1 November 2010
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 78 (3) , S169
Sequential Chemoradiotherapy with 24 Gy of Cranial Irradiation for Intracranial Germinoma diagnosed with MRI
- 1 October 2009
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 75 (2) , 369-377
Intra-Arterial Infusion Chemotherapy Using Cisplatin With Radiotherapy for Stage III Squamous Cell Carcinoma of the Cervix
- 1 October 2009
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 75 (2) , 369-377
Intra-Arterial Infusion Chemotherapy Using Cisplatin With Radiotherapy for Stage III Squamous Cell Carcinoma of the Cervix